Press Release

To Date: 05th October, 2026 The Manager The Manager BSE Limited NSE Limited P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Mumbai-400001 Complex, (BSE Scrip Code: 544742) Bandra (E), Mumbai- 400051. (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Subject: Press Release Pursuant to Regulation 30(6) read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Exchanges that the Company has issued a Press Release titled “Sai Parenterals Completes the Acquisition of R&D Facility Prathyak Laboratories”. Request you to kindly take the same on record. Thanking you, Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646) Encl: As above Investor Release Sai Parenterals Limited Sai Parenterals Completes the Acquisition of R&D Facility Prathyak Laboratories Hyderabad, 05, October 2026 – Sai Parenterals Limited has completed the acquisition of 60% equity stake in Prathyak Laboratories Private Limited, an operating research and development centre at Genome Valley, Hyderabad, for Rs. 15 crore, funded from the unutilised net proceeds of the Company's initial public offering. Prathyak becomes a direct subsidiary of the Company and has been renamed as Sai Prathyak Laboratories Private Limited. The acquisition replaces the greenfield research centre the Company had originally intended to build and for which an allocation had been earmarked in the objects of the issue. The 60% stake has been acquired for Rs. 15 crore. Prathyak has been in operation for three years and brings 28 research scientists and a development pipeline of 150 SKUs across 86 molecules. Its proven capability lies in lyophilised, liposomal and nano-based complex injectables and in oncology injectables — precisely the areas in which the Company is building its regulated-market injectable franchise. Acquisition of an operating platform rather than constructing one allows development work to begin immediately. It removes the construction cycle and, more significantly, the considerably harder task of assembling a scientific team of this calibre, which would have slowed the pace of a greenfield build. Prathyak’s development work supports the Company’s injectable programme directly. Formulations developed at this R&D centre can be taken into commercial production as the Company’s injectable capacity is expanded and upgraded, shortening the path from development to supply in regulated and semi-regulated markets. The platform also supports the Group’s Australian and New Zealand business, where the renewed supply agreements carry a contractual commitment to introduce new products each year. Development for those launches can now be undertaken within the Group. The residual 40% may be acquired through a Right of First Refusal (ROFR) at the same valuation as the present transaction, to be funded from internal accruals, taking Prathyak to a wholly owned position. Commenting on the acquisition, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said: "Building a research centre from the ground up would have cost us a construction cycle and, far more significantly, the time taken to assemble a scientific team. Prathyak gives us both on day one — 28 research scientists who have worked together for three years, and a pipeline of 150 SKUs across 86 molecules in exactly the complex injectable and oncology areas we are building towards. The value of this acquisition lies in what it enables elsewhere in the Group. Work already completed at this R&D centre can be taken into production as our injectable capacity is expanded. The same R&D team will also develop the new products we are required to launch each year under our Australian agreements. We have acquired 60% today and will move to full ownership at the same valuation. This is a further step in the growth plan we set out at the time of our listing: deeper integration across our own value chain, a faster route from development to commercial supply, and capability built inside the Group instead of with third parties. We will continue to pursue opportunities of this kind, organic and inorganic, that strengthen the platform and create lasting value for our stakeholders." Investor Release About the Company Sai Parenterals Limited is an integrated, IP-led pharmaceutical enterprise operating across two complementary verticals — contract development and manufacturing for Indian and multinational customers, and branded generic formulations sold domestically and exported into regulated and semi-regulated markets. The Company’s portfolio spans 302 commercial products across nine therapeutic areas, supported by 599 approved registrations and 67 dossiers under development, and is manufactured across six facilities, five in India and one in Australia, carrying GMP, WHO-GMP, TGA-Australia and PIC/S accreditations. Through Noumed Pharmaceuticals in Australia and New Zealand, acquired in November 2025, the Company holds one of Australia’s largest private-label OTC portfolios, with 15 exclusive long-term supply agreements covering 526 SKUs and a library of over 451 TGA-approved dossiers. More than 50% of consolidated revenue is contracted under long-term regulated-market agreements. The Company completed its initial public offering in March 2026 and was listed on the BSE and the NSE on April 02, 2026. Safe Harbor Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors. For more information, please contact Company: Investor Relations (IR) Sai Parenterals Limited Strategic Growth Advisors Pvt. Ltd. CIN: U24231TG2001PLC036043 CIN: U74140MH2010PTC204285 Mr. Anil Kumar, CFO Ms. Drashti Shah / Mr. Parin Narichania ir@saiparenterals.com drashti.shah@sgapl.net / parin.n@sgapl.net +91 87672 24443 / +91 99300 25733 saiparenterals.com www.sgapl.net